Table 5.

RAS status and pattern of colon cancer metastases

Ref.	n (%MT)	Results	P
Cejas et al[29]	110 (34% KRAS MT)	Frequency of KRAS mutation	0.054
		in primary tumor of patients with lung vs liver metastases
		59% vs 32%
Tie et al[10]	Cohort A	Mutation frequencies	0.003
	161 (48.4% KRAS MT)	in lung in KRAS MT vs WT
		62% vs 38%
		Mutation frequencies in brain	0.003
		in KRAS MT vs WT
		56.5% vs 43.5%
	Cohort C	Relapse in lung in KRAS MT	0.007
	859 (33.8% KRAS MT)	HR 2.1, 95%CI: 1.2-3.5
Kim et al[23]	143 (43.4% KRAS MT)	Lung as initial metastatic site in KRAS MT vs WT	0.003
		45.3% vs 22.1%
		Liver as initial metastatic site in KRAS MT vs WT	< 0.001
		37.3% vs 70.6%
		Distant lymph node as initial metastatic site in KRAS MT vs WT	0.025
		6.7% vs 19.1%
Vauthey et al[25]	193 (18% All RAS MT)	3-yr lung RFS rate in patients undergoing curative resection of liver metastases in RAS MT vs WT	< 0.001
		34.6% vs 59.3%
Yaeger et al[11]	918 (48% All RAS MT)	Lung as site of first metastasis	< 0.01
		in RAS MT vs WT
		22% vs%
		Cumulative incidence of lung as subsequent metastasis at 2 yr after diagnosis in RAS MT vs WT	< 0.001
		32.5% vs 19%
Kemeny et al[24]	169 (30% KRAS MT)	3-yr cumulative recurrence rate to lung after hepatic resection and HAI in KRAS MT vs WT	< 0.01
		58% vs 32%	0.05
		3-yr cumulative recurrence rate to brain after hepatic resection and HAI in KRAS MT vs WT
		14.5% vs 2%	< 0.01
		3-yr cumulative recurrence rate to bone after hepatic resection and HAI in KRAS MT vs WT
		13.4% vs 2%	0.002
Pereira et al[13]	494 (41% KRAS MT)	Time to lung metastasis (median months) in KRAS MT vs WT
		15.2 vs 22.4 (HR 1.4)

n: Total number of patients; %MT: %patients with mutation; MT: Mutant; WT: Wild type; RFS: Recurrence free survival; HAI: Hepatic arterial infusion.